Catheter versus surgical valve replacement for bicuspid valve aortic stenosis
Compares catheter and surgical valve replacement in bicuspid aortic stenosis.
Key facts
- Who runs it
- Cedars-Sinai Medical Center
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Bicuspid Aortic Valve Replacement: Evaluation of Transcatheter Versus Surgery-Pilot Trial
- Status
- Recruiting
- People taking part
- 250 people, planned
- Started
- 31 Jan 2025
- Expected to end
- 1 Feb 2037
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- transcatheter aortic valve replacement (TAVR)
- surgical aortic valve replacement (SAVR)
- Record updated
- 10 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people over 50 with severe narrowing of the aortic heart valve (aortic stenosis) and a bicuspid valve (a valve with two flaps instead of three). People are randomly assigned to a valve replacement through a catheter (TAVR) or by open surgery (SAVR).
- Age
- Older than 50 years
- Sex
- All sexes
- Disease stage
- Severe aortic stenosis that the site judges needs treatment with SAVR or TAVR. Both procedures must be possible for the person, as judged by the heart team.
- Earlier treatment
- Cannot join with an existing TAVR or SAVR valve, or a heart or blood vessel procedure in the prior 30 days.
- Biomarker or test result
- A gated contrast CT scan that the core laboratory can analyse. Bicuspid valve confirmed by CT core laboratory analysis.
Main reasons for not taking part
- Pregnancy or breastfeeding
- Extreme or very high risk with TAVR or SAVR, or much higher risk with one than the other
- Widened aorta (AA≥ 45 mm), or planned aorta surgery
- Planned treatment of other non-coronary heart disease during surgery, such as other valve surgery
- Coronary artery disease needing treatment with Syntax score ≥ 32, or where PCI or CABG cannot be done
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged > 50 years of age
- Site-determined severe AS deemed necessary for treatment with SAVR or TAVR
- Gated contrast CT available and suitable for core laboratory analysis
- BAV anatomy confirmed by CT core laboratory analysis
Who cannot take part
- Recent cardiovascular intervention within the prior 30 days
- Site plan for treatment of concomitant non-coronary cardiovascular disease in the event of randomization to surgery (for instance, concomitant valve surgery, septal defect or coarctation repair, aorta or root replacement or repair)
- In the presence of coronary artery disease deemed necessary for revascularization in the event of randomization to SAVR or TAVR, Syntax score ≥ 32 or deemed unsuitable for PCI, or deemed unsuitable for coronary artery bypass grafting (CABG)
- Associated aortopathy (AA≥ 45 mm by maximal cross-sectional dimension, as confirmed by CT core laboratory analysis, or AA<45 mm but site plan for surgery of the aorta in the event of randomization to surgery
- Presence of an existing TAVR or SAVR device
- Pregnancy or lactation
- Extreme or prohibitive TAVR or SAVR risk, determined by site or committee Active enrollment in another investigational study
- Disproportionate TAVR vs SAVR risk, as determined by treating site or committee
Where in United States
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Mitch GheorghiuTaking people
About the trial
What the trial wants to find out
The study protocol is a randomized trial of standard of care therapies for severe aortic stenosis (AS) in patients with a bicuspid aortic valve (BAV). Namely, the therapies to which patients will be randomized will be transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR), in patients deemed clinically suitable for both following heart team review.
Read full original descriptionShow less
The purpose of this study is to compare the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) versus Surgical Aortic Valve Replacement (SAVR) for treating patients with severe aortic stenosis (AS) who have a congenital bicuspid aortic valve (BAV) anatomy. Patients with BAV anatomy have been under-represented in previous trials and this study might provide important information to help guide future treatment options.
The study patients will be followed with standard of care procedures for 10 years.
The 2 groups in the trial
- transcatheter aortic valve replacement (TAVR)Existing treatment, for comparison
50% of patients will be treated with standard TAVR procedure and followed up for 10 years
- surgical aortic valve replacement (SAVR)Existing treatment, for comparison
50% of patients will be treated with standard SAVR procedure and followed up for 10 years
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Bicuspid Aortic Valve Replacement: EvaLuatIon of transcathetEr Versus surgEry-PILOT Trial
- Plain-language title
- Catheter versus surgical valve replacement for bicuspid valve aortic stenosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 10 February 2025